RE:RE:RE:RE:RE:Nice surprise....langosta wrote: Oh Boy! I have to take Ben and Bunge off 'ignore' I'm missing a lot of fun here. I'm always torn between missing some of their good posts and finding their 'back and forth', a wee bit tiresome.
You haven't missed anything other than bencrook picking on Bunge and Bunge squawking that he is being picked on. I think the pressure of pumping this stock for 5 years only to see the sp still in the mid 30 cent range is finally getting to good old ben the sheppard of the flock.
I found it amusing when in the last PR Mandel referred to Theralase as a " young " company. My how 23 years just flys by I guess.
Interesting that they are still sticking with their 100 patient, multiple sites in Canada, the US and Europe phase 2 trial guidance. What they didn't clarify was if that was supposed to happen in stages and if so how long. If in stages I can see the trial conclusion stretching out considerably.
What's next? Report on patient 6, wait for the regulatory approvals to come down and then hold a brokered PP in the first quarter of 2019. Probably in Feb or March. In the meantime the company will need to pump up the sp to take into account the discount they will have to give the capital market investors. If all goes well they might start treating their first patients by early summer of 2019.